Obio Technology (Shanghai) Corp., Ltd.

688238

CNE1000059N9

OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in the research and development and production of recombinant viruses for gene therapy. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The Company mainly conducts business in the European and American markets and the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Obio Technology (Shanghai) Corp., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.2 CNY

Average target price

8.2 CNY

Spread / Average Target

+32.26%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	-31.03%	556M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
6.2 ^CNY	-7.32%		+0.49%	-31.03%

Apr. 28	Obio Technology Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 23	Obio Technology Corp., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Obio Technology Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 28	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Obio Launches Gmp Production Facility Intelli-M to Expedite Innovative and Advanced Therapies to Patients Who Are in Need	23-09-27	CI
Obio Technology Corp., Ltd.(XSSC:688238) added to S&P Global BMI Index	23-09-18	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange Composite Index	23-03-22	CI
Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange A Share Index	23-03-22	CI
Certain A Shares of Obio Technology Corp., Ltd. are subject to a Lock-Up Agreement Ending on 22-MAR-2023.	23-03-21	CI
Obio Technology Posts 24.6% Drop in 2022 Profit	23-02-27	MT
Obio Technology Corp., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Obio Technology to Invest Another $3 Million on US Subsidiary	23-02-06	MT
OBiO Technology Corp., Ltd. Announces United States Food and Drug Administration Accepts Its GMP Plasmid DNA Drug Master File	23-01-16	CI
Obio Technology Eyes 129 Million Yuan Purchase of Public Rental Housing For Staff	22-12-08	MT
Obio Technology Corp., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Obio Zhizao Gene Technology Co., Ltd announced that it has received CNY 600 million in funding from Obio Technology Corp., Ltd.	22-07-06	CI